Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 9/20 | 0.69 |
| ▸ | PDE4B | Q07343 | 9/20 | 0.69 |
| ▸ | PDE4C | Q08493 | 9/20 | 0.69 |
| ▸ | PDE4D | Q08499 | 9/20 | 0.69 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29893357 | 1.00 | PDE4A (0.69) | PDE4APDE4BPDE4CPDE4DMAPT | |
| SCHEMBL23443637 | 0.96 | PDE4A (0.64) | PDE4APDE4BPDE4CPDE4DMAPT | |
| SCHEMBL23409921 | 0.90 | PDE4A (0.55) | PDE4APDE4BPDE4CPDE4DMAPT | |
| SCHEMBL23410164 | 0.90 | PDE4A (0.55) | PDE4APDE4BPDE4CPDE4DMAPT | |
| SCHEMBL29892224 | 0.89 | PDE4A (0.55) | PDE4APDE4BPDE4CPDE4DMAPT | |
| SCHEMBL23409914 | 0.89 | PDE4A (0.55) | PDE4APDE4BPDE4CPDE4DMAPT | |
| SCHEMBL23409945 | 0.85 | PDE4A (0.50) | PDE4APDE4BPDE4CPDE4DMAPT | |
| SCHEMBL23409851 | 0.83 | PDE4D (0.48) | PDE4APDE4BPDE4CPDE4DMAPT | |
| SCHEMBL29892471 | 0.83 | PDE4D (0.48) | PDE4APDE4BPDE4CPDE4DMAPT | |
| SCHEMBL29892742 | 0.79 | PDE4D (0.45) | PDE4APDE4BPDE4CPDE4DMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230013304-A1 | N2-ARYLMETHYL-4-HALOALKYL-PYRIDAZIN-3-ONE CFTR MODULATORS FOR THE TREATMENT OF CYSTIC FIBROSIS | ECOLE NORMALE SUPERIEURE DE LYON (FR) | 2023-01-19 | — | — | US | claimed |
| WO-2021105641-A1 | N2-ARYLMETHYL-4-HALOALKYL-PYRIDAZIN-3-ONE CFTR MODULATORS FOR THE TREATMENT OF CYSTIC FIBROSIS | UNIVERSITE DE REIMS CHAMPAGNE-ARDENNE (FR) | 2021-06-03 | — | — | WO | claimed |
| US-20230013304-A1 | N2-ARYLMETHYL-4-HALOALKYL-PYRIDAZIN-3-ONE CFTR MODULATORS FOR THE TREATMENT OF CYSTIC FIBROSIS | ECOLE NORMALE SUPERIEURE DE LYON (FR) | 2023-01-19 | — | — | US | disclosed |
| CN-114945368-A | N2-arylmethyl-4-haloalkyl-pyridazin-3-one compounds and uses thereof | 香槟-阿尔登兰斯大学 | 2022-08-26 | — | — | CN | disclosed |
| WO-2021105641-A1 | N2-ARYLMETHYL-4-HALOALKYL-PYRIDAZIN-3-ONE CFTR MODULATORS FOR THE TREATMENT OF CYSTIC FIBROSIS | UNIVERSITE DE REIMS CHAMPAGNE-ARDENNE (FR) | 2021-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230013304-A1 | N2-ARYLMETHYL-4-HALOALKYL-PYRIDAZIN-3-ONE CFTR MODULATORS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, CLCN2, SCNN1B | PDE4A 513/4885PDE4B 712/4885PDE4C 763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.